Janus Henderson Group
PRQR icon

Janus Henderson Group’s ProQR Therapeutics PRQR Stock Holding History

Janus Henderson Group’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-142,350
Closed -$690K – 1334
2017
Q3 		$690K Sell
142,350
-247,659
-64% -$1.29M ﹤0.01% 1213
2017
Q2 		$2.03M Buy
+390,009
New +$1.94M ﹤0.01% 1103

Other funds holding PRQR

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

Janus Henderson Group's PRQR Position: Q4 2017 in Review

Janus Henderson Group sold out of ProQR Therapeutics (PRQR) in Q4 2017, closing a stake of 142,350 shares — an estimated $690K sold.

Janus Henderson Group first reported a position in PRQR in Q2 2017 and held it in 2 quarters. The position peaked at $2.03M in Q2 2017. 27 funds tracked by Wall St. Rank hold PRQR as of Q4 2017.

  • Janus Henderson Group reported no remaining ProQR Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Janus Henderson Group sold 142,350 ProQR Therapeutics shares in Q4 2017, an estimated $690K.
  • Janus Henderson Group first reported a position in ProQR Therapeutics in Q2 2017 and held it in 2 quarters.
  • Janus Henderson Group's ProQR Therapeutics position peaked at $2.03M in Q2 2017.
  • 27 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2017.

Based on Janus Henderson Group's 13F filing for Q4 2017, filed 9 Feb 2018.